Tags

Type your tag names separated by a space and hit enter

Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase.
Pharm Biol. 2014 Jan; 52(1):68-73.PB

Abstract

CONTEXT

Mangiferin has been reported to possess antidiabetic activities. Norathyriol, a xanthone aglycone, has the same structure as mangiferin, except for a C-glucosyl bond. To our best knowledge, no study has been conducted to determine and compare those two compounds on glucose consumption in vitro.

OBJECTIVE

In this study, the effects of norathyriol and mangiferin on glucose consumption in normal and insulin resistance (IR) L6 myotubes were evaluated. Simultaneously, the potential mechanism of this effect was also investigated.

MATERIALS AND METHODS

Normal or IR L6 myotubes were incubated with norathyriol (2.5 ∼ 10 μM, 0.625 ∼ 2.5 μM), mangiferin (10 ∼ 40 μM, 2.5 ∼ 10 μM) or rosiglitazone (20 μM) and/or 0.05 nM insulin for 24 h, respectively. The glucose consumption was assessed using the glucose oxidase method. Immunoblotting was performed to detect protein kinase B (PKB/Akt) and AMP-activated protein kinase (AMPK) phosphorylation in L6 myotubes cells.

RESULTS

Norathyriol and mangiferin treatment alone increased the glucose consumption 61.9 and 56.3%, respectively, in L6 myotubes and made additional increasing with 0.05 nM insulin. In IR L6 myotubes, norathyriol treatment made increasing with or without insulin, mangiferin treatment also made increasing but only when co-treated with insulin. Immunoblotting results showed that norathyriol and mangiferin produced an increase of 1.9 - and 1.8-fold in the phosphorylation levels of the AMPK, but not in Akt.

DISCUSSION AND CONCLUSION

Our findings suggest that norathyriol and mangiferin could improve the glucose utilization and insulin sensitivity by up-regulation of the phosphorylation of AMPK. Norathyriol may be considered as an active metabolite responsible for the antidiabetic activity of mangiferin.

Authors+Show Affiliations

Biomedical Engineering Research Center, Kunming Medical University , Kunming , China .No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24033319

Citation

Wang, Fang, et al. "Mangiferin and Its Aglycone, Norathyriol, Improve Glucose Metabolism By Activation of AMP-activated Protein Kinase." Pharmaceutical Biology, vol. 52, no. 1, 2014, pp. 68-73.
Wang F, Yan J, Niu Y, et al. Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase. Pharm Biol. 2014;52(1):68-73.
Wang, F., Yan, J., Niu, Y., Li, Y., Lin, H., Liu, X., Liu, J., & Li, L. (2014). Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase. Pharmaceutical Biology, 52(1), 68-73. https://doi.org/10.3109/13880209.2013.814691
Wang F, et al. Mangiferin and Its Aglycone, Norathyriol, Improve Glucose Metabolism By Activation of AMP-activated Protein Kinase. Pharm Biol. 2014;52(1):68-73. PubMed PMID: 24033319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mangiferin and its aglycone, norathyriol, improve glucose metabolism by activation of AMP-activated protein kinase. AU - Wang,Fang, AU - Yan,Juming, AU - Niu,Yanfen, AU - Li,Yan, AU - Lin,Hua, AU - Liu,Xu, AU - Liu,Jikai, AU - Li,Ling, Y1 - 2013/09/13/ PY - 2013/9/17/entrez PY - 2013/9/17/pubmed PY - 2014/9/10/medline SP - 68 EP - 73 JF - Pharmaceutical biology JO - Pharm Biol VL - 52 IS - 1 N2 - CONTEXT: Mangiferin has been reported to possess antidiabetic activities. Norathyriol, a xanthone aglycone, has the same structure as mangiferin, except for a C-glucosyl bond. To our best knowledge, no study has been conducted to determine and compare those two compounds on glucose consumption in vitro. OBJECTIVE: In this study, the effects of norathyriol and mangiferin on glucose consumption in normal and insulin resistance (IR) L6 myotubes were evaluated. Simultaneously, the potential mechanism of this effect was also investigated. MATERIALS AND METHODS: Normal or IR L6 myotubes were incubated with norathyriol (2.5 ∼ 10 μM, 0.625 ∼ 2.5 μM), mangiferin (10 ∼ 40 μM, 2.5 ∼ 10 μM) or rosiglitazone (20 μM) and/or 0.05 nM insulin for 24 h, respectively. The glucose consumption was assessed using the glucose oxidase method. Immunoblotting was performed to detect protein kinase B (PKB/Akt) and AMP-activated protein kinase (AMPK) phosphorylation in L6 myotubes cells. RESULTS: Norathyriol and mangiferin treatment alone increased the glucose consumption 61.9 and 56.3%, respectively, in L6 myotubes and made additional increasing with 0.05 nM insulin. In IR L6 myotubes, norathyriol treatment made increasing with or without insulin, mangiferin treatment also made increasing but only when co-treated with insulin. Immunoblotting results showed that norathyriol and mangiferin produced an increase of 1.9 - and 1.8-fold in the phosphorylation levels of the AMPK, but not in Akt. DISCUSSION AND CONCLUSION: Our findings suggest that norathyriol and mangiferin could improve the glucose utilization and insulin sensitivity by up-regulation of the phosphorylation of AMPK. Norathyriol may be considered as an active metabolite responsible for the antidiabetic activity of mangiferin. SN - 1744-5116 UR - https://www.unboundmedicine.com/medline/citation/24033319/Mangiferin_and_its_aglycone_norathyriol_improve_glucose_metabolism_by_activation_of_AMP_activated_protein_kinase_ L2 - http://www.tandfonline.com/doi/full/10.3109/13880209.2013.814691 DB - PRIME DP - Unbound Medicine ER -